MicroRNA and multiple myeloma: From laboratory findings to translational therapeutic approaches

Current Pharmaceutical Biotechnology

Volumn 15, Issue 5, 2014, Pages 459-467

  Tassone, Pierfrancesco ^a,b   Amodio, Nicola ^a   Di Martino, Maria Teresa ^a   Rossi, Marco ^a   Tagliaferri, Pierosandro ^a   Cho, William C ^c  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b Temple University   (United States)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

Bone disease; microRNA; Multiple myeloma; Non coding RNA; Target therapy

Indexed keywords

MICRORNA; MICRORNA 106B; MICRORNA 15; MICRORNA 16; MICRORNA 17; MICRORNA 181A; MICRORNA 181B; MICRORNA 192; MICRORNA 194; MICRORNA 21; MICRORNA 214; MICRORNA 215; MICRORNA 221; MICRORNA 222; MICRORNA 25; MICRORNA 32; MICRORNA 34A; MICRORNA 92; PROTEIN P53; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOGENESIS; BIOLOGICAL ACTIVITY; BONE DISEASE; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; DEREGULATION; GENE EXPRESSION; GENOMIC INSTABILITY; HIGH THROUGHPUT SEQUENCING; HUMAN; HYBRIDIZATION; IN SITU HYBRIDIZATION; MULTIPLE MYELOMA; NONHUMAN; NORTHERN BLOTTING; ONCOGENE RAS; PATHOGENESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; TRANSLATIONAL RESEARCH; ANIMAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MULTIPLE MYELOMA; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84907171169     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666140519104743     Document Type: Article

References (89)

1. Kyle, R. A.; Therneau, T. M.; Rajkumar, S. V.; Offord, J. R.; Larson, D. R.; Plevak, M. F.; Melton, L. J. 3rd. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med., 2002, 346(8), 564-569.
2. Morabito, F.; Recchia, A. G.; Mazzone, C.; Gentile, M. Targeted therapy of multiple myeloma: The changing paradigm at the beginning of the new millennium. Curr. Cancer Drug Targets, 2012, 12(7), 743-756.
3. Tassone, P.; Tagliaferri, P.; Rossi, M.; Gaspari, M.; Terracciano, R.; Venuta, S. Genetics and molecular profiling of multiple myeloma: novel tools for clinical management? Eur. J. Cancer, 2006, 42(11), 1530-1538.
4. Tassone, P.; Tagliaferri, P.; Rossi, M.; Calimeri, T.; Bulotta, A.; Abbruzzese, A.; Caraglia, M.; Neri, P. Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy. Curr. Cancer Drug Targets, 2009, 9(7), 854-870.
5. Bartel, D. P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell, 2004, 116 (2), 281-297.
6. Bartel, D. P. MicroRNAs: Target recognition and regulatory functions. Cell, 2009, 136 (2), 215-233.
7. Ambros, V. The functions of animal microRNAs. Nature, 2004, 431(7006), 350-355.
8. Rodriguez, A.; Griffiths-Jones, S.; Ashurst, J. L.; Bradley, A. Identification of mammalian microRNA host genes and transcription units. Genome Res., 2004, 14(10A), 1902-1910.
9. Farazi, T. A.; Hoell, J. I.; Morozov, P.; Tuschl, T. MicroRNAs in human cancer. Adv. Exp. Med. Biol., 2013, 774, 1-20.
10. Yuan, X.; Liu, C.; Yang, P.; He, S.; Liao, Q.; Kang, S.; Zhao, Y. Clustered microRNAs' coordination in regulating protein-protein interaction network. BMC Syst. Biol., 2009, 3, 65.
11. Liu, C.; Mallick, B.; Long, D.; Rennie, W. A.; Wolenc, A.; Carmack, C. S.; Ding, Y. CLIP-based prediction of mammalian microRNA binding sites. Nucleic Acids Res., 2013, 41(14), e138.
12. Yang, J. S.; Lai, E. C. Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants. Mol. Cell, 2011, 43(6), 892-903.
13. Mu, P.; Han, Y. C.; Betel, D.; Yao, E.; Squatrito, M.; Ogrodowski, P.; de Stanchina, E.; D'Andrea, A.; Sander, C.; Ventura, A. Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Develop., 2009, 23(24), 2806-2811.
14. Creighton, C. J.; Reid, J. G.; Gunaratne, P. H. Expression profiling of microRNAs by deep sequencing. Brief Bioinform., 2009, 10(5), 490-497.
15. Geiss, G. K.; Bumgarner, R. E.; Birditt, B.; Dahl, T.; Dowidar, N.; Dunaway, D. L.; Fell, H. P.; Ferree, S.; George, R. D.; Grogan, T.; James, J. J.; Maysuria, M.; Mitton, J. D.; Oliveri, P.; Osborn, J. L.; Peng, T.; Ratcliffe, A. L.; Webster, P. J.; Davidson, E. H.; Hood, L.; Dimitrov, K. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat. Biotechnol., 2008, 26(3), 317-325.
16. Van Rooij, E. The art of microRNA research. Circulat. Res., 2011, 108(2), 219-234.
17. Pritchard, C. C.; Cheng, H. H.; Tewari, M. MicroRNA profiling: Approaches and considerations. Nat. Rev. Genet., 2012, 13(5), 358-369.
18. Pall, G. S.; Codony-Servat, C.; Byrne, J.; Ritchie, L.; Hamilton, A. Carbodiimide-mediated cross-linking of RNA to nylon membranes improves the detection of siRNA, miRNA and piRNA by northern blot. Nucleic Acids Res., 2007, 35(8), e60.
19. Chen, C.; Ridzon, D. A.; Broomer, A. J.; Zhou, Z.; Lee, D. H.; Nguyen, J. T.; Barbisin, M.; Xu, N. L.; Mahuvakar, V. R.; Andersen, M. R.; Lao, K. Q.; Livak, K. J.; Guegler, K. J. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res., 2005, 33(20), e179.
20. Wienholds, E.; Kloosterman, W. P.; Miska, E.; Alvarez-Saavedra, E.; Berezikov, E.; de Bruijn, E.; Horvitz, H. R.; Kauppinen, S.; Plasterk, R. H. MicroRNA expression in zebrafish embryonic development. Science, 2005, 309(5732), 310-311.
21. Valoczi, A.; Varallyay, E.; Kauppinen, S.; Burgyan, J.; Havelda, Z. Spatio-temporal accumulation of microRNAs is highly coordinated in developing plant tissues. Plant J., 2006, 47(1), 140-151.
22. Reyes-Herrera, P. H.; Ficarra, E.; Acquaviva, A.; Macii, E. miREE: miRNA recognition elements ensemble. BMC Bioinformat., 2011, 12, 454.
23. Lindow, M.; Gorodkin, J. Principles and limitations of computational microRNA gene and target finding. DNA Cell Biol., 2007, 26(5), 339-351.
24. Rajewsky, N. MicroRNA target predictions in animals. Nat. Genet., 2006, 38(Suppl), S8-13.
25. Barbato, C.; Arisi, I.; Frizzo, M. E.; Brandi, R.; Da Sacco, L.; Masotti, A. Computational challenges in miRNA target predictions: to be or not to be a true target? J. Biomed. Biotechnol., 2009, 803069.
26. Sethupathy, P.; Megraw, M.; Hatzigeorgiou, A. G. A guide through present computational approaches for the identification of mammalian microRNA targets. Nat. Methods, 2006, 3(11), 881-886.
27. Thomas, M.; Lieberman, J.; Lal, A. Desperately seeking microRNA targets. Nat. Struct. Mol. Biol., 2010, 17(10), 1169-1174.
28. Lee, D.; Shin, C. MicroRNA-target interactions: new insights from genome-wide approaches. Ann. N. Y. Acad. Sci., 2012, 1271, 118-128.
29. Thomson, D. W.; Bracken, C. P.; Goodall, G. J. Experimental strategies for microRNA target identification. Nucleic Acids Res., 2011, 39(16), 6845-6853.
30. Sun, K.; Lai, E. C. Adult-specific functions of animal microRNAs. Nat. Rev. Gene., 2013, 14(8), 535-548.
31. Cheng, A. M.; Byrom, M. W.; Shelton, J.; Ford, L. P. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res., 2005, 33(4), 1290-1297.
32. Tanno, B.; Cesi, V.; Vitali, R.; Sesti, F.; Giuffrida, M. L.; Mancini, C.; Calabretta, B.; Raschella, G. Silencing of endogenous IGFBP-5 by microRNA interference affects proliferation, apoptosis and differentiation of neuroblastoma cells. Cell Death Differ., 2005, 12(3), 213-223.
33. Calin, G. A.; Dumitru, C. D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.; Rai, K.; Rassenti, L.; Kipps, T.; Negrini, M.; Bullrich, F.; Croce, C. M. Frequent deletions and down-regulation of microRNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA, 2002, 99(24), 15524-15529.
34. Chang, T. C.; Wentzel, E. A.; Kent, O. A.; Ramachandran, K.; Mullendore, M.; Lee, K. H.; Feldmann, G.; Yamakuchi, M.; Ferlito, M.; Lowenstein, C. J.; Arking, D. E.; Beer, M. A.; Maitra, A.; Mendell, J. T. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell, 2007, 26(5), 745-752.
35. He, L.; He, X.; Lowe, S. W.; Hannon, G. J. MicroRNAs join the p53 network-another piece in the tumour-suppression puzzle. Nat. Rev. Cancer, 2007, 7(11), 819-822.
36. Wong, K. Y.; Huang, X.; Chim, C. S. DNA methylation of microRNA genes in multiple myeloma. Carcinogenesis, 2012, 33(9), 1629-1638.
37. Kumar, M. S.; Lu, J.; Mercer, K. L.; Golub, T. R.; Jacks, T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet., 2007, 39(5), 673-677.
38. Mayr, C.; Hemann, M. T.; Bartel, D. P. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science, 2007, 315(5818), 1576-1579.
39. Melo, S. A.; Ropero, S.; Moutinho, C.; Aaltonen, L. A.; Yamamoto, H.; Calin, G. A.; Rossi, S.; Fernandez, A. F.; Carneiro, F.; Oliveira, C.; Ferreira, B.; Liu, C. G.; Villanueva, A.; Capella, G.; Schwartz, S., Jr.; Shiekhattar, R.; Esteller, M. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat. Genet., 2009, 41(3), 365-370.
40. Lambertz, I.; Nittner, D.; Mestdagh, P.; Denecker, G.; Vandesompele, J.; Dyer, M. A.; Marine, J. C. Monoallelic but not biallelic loss of Dicer1 promotes tumorigenesis in vivo. Cell Death Differ., 2010, 17(4), 633-641.
41. Pichiorri, F.; Suh, S. S.; Ladetto, M.; Kuehl, M.; Palumbo, T.; Drandi, D.; Taccioli, C.; Zanesi, N.; Alder, H.; Hagan, J. P.; Munker, R.; Volinia, S.; Boccadoro, M.; Garzon, R.; Palumbo, A.; Aqeilan, R. I.; Croce, C. M. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc. Natl. Acad. Sci. USA, 2008, 105(35), 12885-12890.
42. Zhou, Y.; Chen, L.; Barlogie, B.; Stephens, O.; Wu, X.; Williams, D. R.; Cartron, M. A.; van Rhee, F.; Nair, B.; Waheed, S.; Pineda-Roman, M.; Alsayed, Y.; Anaissie, E.; Shaughnessy, J. D., Jr. Highrisk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc. Natl. Acad. Sci. USA, 2010, 107(17), 7904-7909.
43. Lionetti, M.; Biasiolo, M.; Agnelli, L.; Todoerti, K.; Mosca, L.; Fabris, S.; Sales, G.; Deliliers, G. L.; Bicciato, S.; Lombardi, L.; Bortoluzzi, S.; Neri, A. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood, 2009, 114(25), e20-26.
44. Gutierrez, N. C.; Sarasquete, M. E.; Misiewicz-Krzeminska, I.; Delgado, M.; De Las Rivas, J.; Ticona, F. V.; Ferminan, E.; Martin-Jimenez, P.; Chillon, C.; Risueno, A.; Hernandez, J. M.; Garcia-Sanz, R.; Gonzalez, M.; San Miguel, J. F. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia, 2010, 24(3), 629-637.
45. Lionetti, M.; Musto, P.; Di Martino, M. T.; Fabris, S.; Agnelli, L.; Todoerti, K.; Tuana, G.; Mosca, L.; Gallo Cantafio, M. E.; Grieco, V.; Bianchino, G.; D'Auria, F.; Statuto, T.; Mazzoccoli, C.; De Luca, L.; Petrucci, M. T.; Offidani, M.; Di Raimondo, F.; Falcone, A.; Caravita, T.; Omede, P.; Morabito, F.; Tassone, P.; Boccadoro, M.; Palumbo, A.; Neri, A. Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin. Cancer Res., 2013, 19(12), 3130-3142.
46. Unno, K.; Zhou, Y.; Zimmerman, T.; Platanias, L. C.; Wickrema, A. Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma. Leukemia Lymphoma, 2009, 50(11), 1865-1871.
47. Pichiorri, F.; Suh, S. S.; Rocci, A.; De Luca, L.; Taccioli, C.; Santhanam, R.; Zhou, W.; Benson, D. M., Jr.; Hofmainster, C.; Alder, H.; Garofalo, M.; Di Leva, G.; Volinia, S.; Lin, H. J.; Perrotti, D.; Kuehl, M.; Aqeilan, R. I.; Palumbo, A.; Croce, C. M. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell, 2010, 18(4), 367-381.
48. Loffler, D.; Brocke-Heidrich, K.; Pfeifer, G.; Stocsits, C.; Hackermuller, J.; Kretzschmar, A. K.; Burger, R.; Gramatzki, M.; Blumert, C.; Bauer, K.; Cvijic, H.; Ullmann, A. K.; Stadler, P. F.; Horn, F. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood, 2007, 110(4), 1330-1333.
49. Tassone, P.; Galea, E.; Forciniti, S.; Tagliaferri, P.; Venuta, S. The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. Int. J. Oncol., 2002, 21(4), 867-873.
50. Tassone, P.; Neri, P.; Burger, R.; Savino, R.; Shammas, M.; Catley, L.; Podar, K.; Chauhan, D.; Masciari, S.; Gozzini, A.; Tagliaferri, P.; Venuta, S.; Munshi, N. C.; Anderson, K. C. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin. Cancer Res., 2005, 11(11), 4251-4258.
51. Fulciniti, M.; Hideshima, T.; Vermot-Desroches, C.; Pozzi, S.; Nanjappa, P.; Shen, Z.; Patel, N.; Smith, E. S.; Wang, W.; Prabhala, R.; Tai, Y. T.; Tassone, P.; Anderson, K. C.; Munshi, N. C. A highaffinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin. Cancer Res., 2009, 15(23), 7144-7152.
52. Wang, X.; Li, C.; Ju, S.; Wang, Y.; Wang, H.; Zhong, R. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation. Leukemia Lymphoma, 2011, 52(10), 1991-1998.
53. Leone, E.; Morelli, E.; Di Martino, M. T.; Amodio, N.; Foresta, U.; Gulla, A.; Rossi, M.; Neri, A.; Giordano, A.; Munshi, N. C.; Anderson, K. C.; Tagliaferri, P.; Tassone, P. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin. Cancer Res., 2013.
54. Roccaro, A. M.; Sacco, A.; Thompson, B.; Leleu, X.; Azab, A. K.; Azab, F.; Runnels, J.; Jia, X.; Ngo, H. T.; Melhem, M. R.; Lin, C. P.; Ribatti, D.; Rollins, B. J.; Witzig, T. E.; Anderson, K. C.; Ghobrial, I. M. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood, 2009, 113(26), 6669-6680.
55. Di Martino, M. T.; Gulla, A.; Cantafio, M. E.; Lionetti, M.; Leone, E.; Amodio, N.; Guzzi, P. H.; Foresta, U.; Conforti, F.; Cannataro, M.; Neri, A.; Giordano, A.; Tagliaferri, P.; Tassone, P. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget, 2013, 4(2), 242-255.
56. Medina, R.; Zaidi, S. K.; Liu, C. G.; Stein, J. L.; Van Wijnen, A. J.; Croce, C. M.; Stein, G. S. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res., 2008, 68(8), 2773-2780.
57. Chen, L.; Li, C.; Zhang, R.; Gao, X.; Qu, X.; Zhao, M.; Qiao, C.; Xu, J.; Li, J. miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Cancer Lett., 2011, 309(1), 62-70.
58. Gao, X.; Zhang, R.; Qu, X.; Zhao, M.; Zhang, S.; Wu, H.; Jianyong, L.; Chen, L. miR-15a, miR-16-1 and miR-17-92 cluster expression are linked to poor prognosis in multiple myeloma. Leukemia Res., 2012, 36(12), 1505-1509.
59. Todoerti, K.; Barbui, V.; Pedrini, O.; Lionetti, M.; Fossati, G.; Mascagni, P.; Rambaldi, A.; Neri, A.; Introna, M.; Lombardi, L.; Golay, J. Pleiotropic anti-myeloma activity of ITF2357: Inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. Haematologica, 2010, 95(2), 260-269.
60. Ballabio, E.; Armesto, M.; Breeze, C. E.; Manterola, L.; Arestin, M.; Tramonti, D.; Hatton, C. S.; Lawrie, C. H. Bortezomib action in multiple myeloma: Microrna-mediated synergy (and miR-27a/CDK5 driven sensitivity). Blood Cancer J., 2012, 2, e83.
61. Misiewicz-Krzeminska, I.; Sarasquete, M. E.; Quwaider, D.; Krzeminski, P.; Ticona, F. V.; Paino, T.; Delgado, M.; Aires, A.; Ocio, E. M.; Garcia-Sanz, R.; San Miguel, J. F.; Gutierrez, N. C. Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication. Haematologica, 2013, 98(4), 640-648.
62. Sarasquete, M. E.; Gutierrez, N. C.; Misiewicz-Krzeminska, I.; Paiva, B.; Chillon, M. C.; Alcoceba, M.; Garcia-Sanz, R.; Hernandez, J. M.; Gonzalez, M.; San-Miguel, J. F. Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. Haematologica, 2011, 96(3), 468-471.
63. Duchaine, T. F.; Slack, F. J. RNA interference and microRNAoriented therapy in cancer: Rationales, promises, and challenges. Curr. Oncol., 2009, 16(4), 61-66.
64. Wiggins, J. F.; Ruffino, L.; Kelnar, K.; Omotola, M.; Patrawala, L.; Brown, D.; Bader, A. G. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res., 2010, 70(14), 5923-5930.
65. Trang, P.; Medina, P. P.; Wiggins, J. F.; Ruffino, L.; Kelnar, K.; Omotola, M.; Homer, R.; Brown, D.; Bader, A. G.; Weidhaas, J. B.; Slack, F. J. Regression of murine lung tumors by the let-7 microRNA. Oncogene, 2010, 29(11), 1580-1587.
66. Trang, P.; Wiggins, J. F.; Daige, C. L.; Cho, C.; Omotola, M.; Brown, D.; Weidhaas, J. B.; Bader, A. G.; Slack, F. J. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther., 2011, 19(6), 1116-1122.
67. Sun, C. Y.; She, X. M.; Qin, Y.; Chu, Z. B.; Chen, L.; Ai, L. S.; Zhang, L.; Hu, Y. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis, 2013, 34(2), 426-435.
68. Di Martino, M. T.; Leone, E.; Amodio, N.; Foresta, U.; Lionetti, M.; Pitari, M. R.; Cantafio, M. E.; Gulla, A.; Conforti, F.; Morelli, E.; Tomaino, V.; Rossi, M.; Negrini, M.; Ferrarini, M.; Caraglia, M.; Shammas, M. A.; Munshi, N. C.; Anderson, K. C.; Neri, A.; Tagliaferri, P.; Tassone, P. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin. Cancer Res., 2012, 18(22), 6260-6270.
69. Calimeri, T.; Battista, E.; Conforti, F.; Neri, P.; Di Martino, M. T.; Rossi, M.; Foresta, U.; Piro, E.; Ferrara, F.; Amorosi, A.; Bahlis, N.; Anderson, K. C.; Munshi, N.; Tagliaferri, P.; Causa, F.; Tassone, P. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia, 2011, 25(4), 707-711.
70. Amodio, N.; Leotta, M.; Bellizzi, D.; Di Martino, M. T.; D'Aquila, P.; Lionetti, M.; Fabiani, F.; Leone, E.; Gulla, A. M.; Passarino, G.; Caraglia, M.; Negrini, M.; Neri, A.; Giordano, A.; Tagliaferri, P.; Tassone, P. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget, 2012, 3(10), 1246-1258.
71. Amodio, N.; Di Martino, M. T.; Foresta, U.; Leone, E.; Lionetti, M.; Leotta, M.; Gulla, A. M.; Pitari, M. R.; Conforti, F.; Rossi, M.; Agosti, V.; Fulciniti, M.; Misso, G.; Morabito, F.; Ferrarini, M.; Neri, A.; Caraglia, M.; Munshi, N. C.; Anderson, K. C.; Tagliaferri, P.; Tassone, P. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis., 2012, 3, e436.
72. Amodio, N.; Bellizzi, D.; Leotta, M.; Raimondi, L.; Biamonte, L.; D'Aquila, P.; Di Martino, M. T.; Calimeri, T.; Rossi, M.; Lionetti, M.; Leone, E.; Passarino, G.; Neri, A.; Giordano, A.; Tagliaferri, P.; Tassone, P. miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle, 2013, 12(23), 3650-3662.
73. Di Martino, M. T.; Gulla, A.; Gallo Cantafio, M. E.; Altomare, E.; Amodio, N.; Leone, E.; Morelli, E.; Lio, S. G.; Caracciolo, D.; Rossi, M.; Frandsen, N. M.; Tagliaferri, P.; Tassone, P. In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitormiR-221 against multiple myeloma cells. PloS One, 2014, 9(2), e89659.
74. Rossi, M.; Di Martino, M. T.; Morelli, E.; Leotta, M.; Rizzo, A.; Grimaldi, A.; Misso, G.; Tassone, P.; Caraglia, M. Molecular targets for the treatment of multiple myeloma. Curr. Cancer Drug Targets, 2012, 12(7), 757-767.
75. Terpos, E.; Morgan, G.; Dimopoulos, M. A.; Drake, M. T.; Lentzsch, S.; Raje, N.; Sezer, O.; Garcia-Sanz, R.; Shimizu, K.; Turesson, I.; Reiman, T.; Jurczyszyn, A.; Merlini, G.; Spencer, A.; Leleu, X.; Cavo, M.; Munshi, N.; Rajkumar, S. V.; Durie, B. G.; Roodman, G. D. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J. Clin. Oncol., 2013, 31, (18), 2347-2357.
76. Hageman, K.; Patel, K. C.; Mace, K.; Cooper, M. R. The role of denosumab for prevention of skeletal-related complications in multiple myeloma. Annal. Pharmacol., 2013, 47(7-8), 1069-1074.
77. Rossi, M.; Pitari, M. R.; Amodio, N.; Di Martino, M. T.; Conforti, F.; Leone, E.; Botta, C.; Paolino, F. M.; Del Giudice, T.; Iuliano, E.; Caraglia, M.; Ferrarini, M.; Giordano, A.; Tagliaferri, P.; Tassone, P. miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease. J. Cell Physiol., 2012.
78. Lee, Y.; Kim, H. J.; Park, C. K.; Kim, Y. G.; Lee, H. J.; Kim, J. Y.; Kim, H. H. MicroRNA-124 regulates osteoclast differentiation. Bone, 2013.
79. Zhang, J.; Zhao, H.; Chen, J.; Xia, B.; Jin, Y.; Wei, W.; Shen, J.; Huang, Y. Interferon-beta-induced miR-155 inhibits osteoclast differentiation by targeting SOCS1 and MITF. FEBS Lett., 2012, 586(19), 3255-3262.
80. Chen, C.; Cheng, P.; Xie, H.; Zhou, H. D.; Wu, X. P.; Liao, E. Y.; Luo, X. H. miR-503 regulates osteoclastogenesis via targeting RANK. J. Bone Miner. Res., 2014, 29(2), 338-347.
81. Cho, W. C. MicroRNAs as therapeutic targets and their potential applications in cancer therapy. Expert Opin. Ther. Target, 2012, 16(8), 747-759.
82. Misso, G.; Zappavigna, S.; Castellano, M.; De Rosa, G.; Di Martino, M. T.; Tagliaferri, P.; Tassone, P.; Caraglia, M. Emerging pathways as individualized therapeutic target of multiple myeloma. Expert Opin. Biol. Ther., 2013, 13(Suppl 1), S95-S109.
83. Burnett, J. C.; Rossi, J. J.; Tiemann, K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J., 2011, 6, (9), 1130-1146.
84. Reagan-Shaw, S.; Ahmad, N. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: Implications for the treatment of prostate cancer. FASEB J., 2005, 19(6), 611-613.
85. de Antonellis, P.; Liguori, L.; Falanga, A.; Carotenuto, M.; Ferrucci, V.; Andolfo, I.; Marinaro, F.; Scognamiglio, I.; Virgilio, A.; De Rosa, G.; Galeone, A.; Galdiero, S.; Zollo, M. MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines. Naunyn. Schmiedebergs Arch. Pharmacol., 2013, 386(4), 287-302.
86. Di Martino, M. T.; Campani, V.; Misso, G.; Gallo Cantafio, M. E.; Gulla, A.; Foresta, U.; Guzzi, P. H.; Castellano, M.; Grimaldi, A.; Gigantino, V.; Franco, R.; Lusa, S.; Cannataro, M.; Tagliaferri, P.; De Rosa, G.; Tassone, P.; Caraglia, M. In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PloS One, 2014, 9(2), e90005.
87. Scognamiglio, I.; Di Martino, M. T.; Campani, V.; Virgilio, A.; Galeone, A.; Gulla, A.; Gallo Cantafio, M. E.; Misso, G.; Tagliaferri, P.; Tassone, P.; Caraglia, M.; De Rosa, G. Transferrinconjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma. Biomed. Res. Int., 2014, (14), 217-365.
88. Rossi, M.; Botta, C.; Correale, P.; Tassone, P.; Tagliaferri, P. Immunologic microenvironment and personalized treatment in multiple myeloma. Expert Opin. Biol. Ther., 2013, 13(Suppl 1), S83-93.
89. Janssen, H. L.; Reesink, H. W.; Lawitz, E. J.; Zeuzem, S.; Rodriguez-Torres, M.; Patel, K.; van der Meer, A. J.; Patick, A. K.; Chen, A.; Zhou, Y.; Persson, R.; King, B. D.; Kauppinen, S.; Levin, A. A.; Hodges, M. R. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med., 2013.